Current anticancer treatments essentially target the primary tumor cells that proliferate quickly, but do not effectively eliminate specific cancer cells able to adapt to existing treatments and which exhibit high metastatic potential. Yet metastases are responsible for 70% of cancer deaths.
Iron-activated molecules show promise against aggressive, treatment-resistant cancer cells
